44 completed, 24 recruiting, 20 terminated, 16 unknown. 126 Phase 2, 65 Phase 1, 5 Phase 3.
Follow Advanced Cancer: new trials by email Literature Review of Advanced Cancer trials Research Report on Advanced Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial PEX010 25 mg psilocybin, PEX010 5 mg psilocybin, Standard Psilocybin-Assisted Therapy - Advanced Cancer, Demoralization | Phase 2 | Not yet recruiting | University of Calgary | 60 | 2026-10-30 | 2026-09-02 |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial Psilocybin (high dose), Psilocybin (low dose), PEARL Therapy - Advanced Cancer, Stage IV Solid Tumor Cancer | Phase 2 | Not yet recruiting | University Health Network, Toronto | 46 | 2026-09-14 | 2026-10-15 |
| Phase 1/2 Study of UI-102 in Selected Advanced Cancers UI-102 - Advanced Cancer | Phase 1 / Phase 2 | Recruiting | United Immunity, co., Ltd. | 140 | 2026-05-20 | 2026-06-03 |
| Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) Givastomig, Nivolumab, 5Fluorouracil - Solid Tumor, Advanced Cancer | Phase 2 | Recruiting | I-Mab Biopharma US Limited | 180 | 2026-02-11 | 2026-05-14 |
| A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer Durvalumab or Pembrolizumab, Durvalumab or Pembrolizumab + Levnatinib, Durvalumab or Pembrolizumab + Venadaparib - Biliary Tract Neoplasms, Advanced Cancer | Phase 1 / Phase 2 | Not yet recruiting | Yonsei University | 160 | 2025-12-01 | 2025-12-08 |
| Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer Envafolimab + Gemcitabine + Cisplatin + Simvastatin - Biliary Tract Cancer, Advanced Cancer | Phase 2 | Not yet recruiting | Tongji Hospital | 62 | 2025-06-01 | 2025-06-04 |
| Using Tumor Models to Determine Treatments Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 25 | 2025-04-07 | 2026-06-23 |
| HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC PD-L1 inhibitor, HAIC - ICC, Advanced Cancer | Phase 2 | Recruiting | Eastern Hepatobiliary Surgery Hospital | 50 | 2025-01-01 | 2026-01-23 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors ALK201 - Advanced Cancer, Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Shanghai Allink Biotherapeutics Co., Ltd. | 202 | 2024-10-24 | 2026-05-22 |
| Psilocybin in Cancer Pain Study Psilocybin - Opioid-Related Disorders, Pain Management | Phase 2 | Active not recruiting | Yvan Beaussant, MD, MSci | 15 | 2024-09-23 | 2026-10-27 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer Psilocybin - Advanced Cancer, Stage IV Solid Tumor Cancer | Phase 2 | Active not recruiting | University Health Network, Toronto | 15 | 2024-06-06 | 2026-06-22 |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy - Lung Cancer, Non-small Cell, Lung Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Krystal Biotech, Inc. | 250 | 2024-04-17 | 2025-10-24 |
| NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab - Nanoliposomal Irinotecan, Cadonilimab | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2024-04-17 | 2024-12-24 |
| Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy Psilocybin, Niacin - Depression, Anxiety, Psilocybin-Assisted Psychotherapy | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 48 | 2024-04-16 | 2026-11-03 |
| Personalized Neoantigen Peptide Vaccines for Solid Tumors Personalized Neoantigen Peptide Vaccine - Solid Tumors, Advanced Cancer | Phase 1 / Phase 2 | Recruiting | Seqker Biosciences, Inc. | 10 | 2024-03-01 | 2026-07-24 |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) Adagrasib - Advanced Cancer, Metastatic Cancer | Phase 2 | Active not recruiting | Mirati Therapeutics Inc. | 200 | 2024-02-01 | 2026-08-14 |
| Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer CJRB-101, Pembrolizumab injection - NSCLC, HNSCC | Phase 1 / Phase 2 | Recruiting | CJ Bioscience, Inc. | 160 | 2023-09-11 | 2024-12-20 |
| Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC 177Lu girentuximab, Nivolumab, Cabozantinib - Advanced Cancer, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2023-06-30 | 2026-11-03 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
Showing 20 of 126. Sign in to see all of them.
Neoplasm Metastasis (24) · Carcinoma, Non-Small-Cell Lung (21) · Neoplasms (20) · Pancreatic Neoplasms (13) · Melanoma (12) · Stomach Neoplasms (10) · Breast Neoplasms (7) · Colorectal Neoplasms (7) · Uterine Cervical Neoplasms (7) · Carcinoma, Renal Cell (6) · Carcinoma, Transitional Cell (6) · Ovarian Neoplasms (6) · Sarcoma (6) · Squamous Cell Carcinoma of Head and Neck (6) · Biliary Tract Neoplasms (5)
Neoplasms by Site (62) · Neoplasms (60) · Neoplasms by Histologic Type (37) · Pathological Conditions, Signs and Symptoms (35) · Digestive System Diseases (30) · Digestive System Neoplasms (30) · Respiratory Tract Diseases (27) · Respiratory Tract Neoplasms (27) · Thoracic Neoplasms (27) · Lung Diseases (26) · Pathologic Processes (26) · Neoplasms, Glandular and Epithelial (25) · Bronchial Neoplasms (24) · Carcinoma, Bronchogenic (24) · Neoplastic Processes (24)
Nivolumab (22) · pembrolizumab (18) · Gemcitabine (9) · Ipilimumab (9) · Psilocybin (5) · linrodostat (5) · spartalizumab (5) · Cisplatin (4) · Irinotecan (4) · abemaciclib (4) · relatlimab (4) · Capecitabine (3) · Cetuximab (3) · Cyclophosphamide (3) · Docetaxel (3)
Bristol-Myers Squibb (12) · M.D. Anderson Cancer Center (7) · University Health Network, Toronto (5) · Eli Lilly and Company (4) · Mirati Therapeutics Inc. (3) · Western Regional Medical Center (3) · Henan Cancer Hospital (2) · Merck Sharp & Dohme LLC (2) · NuCana plc (2) · Peking University People's Hospital (2) · Sun Yat-sen University (2) · TaiRx, Inc. (2) · Transcenta Therapeutics (Hangzhou) Co., Ltd. (2) · 7 Hills Pharma, LLC (1) · AIO-Studien-gGmbH (1)
United States (72) · Canada (21) · China (21) · Spain (20) · France (18) · Australia (17) · Italy (16) · United Kingdom (14) · Germany (9) · Taiwan (9) · Poland (8) · South Korea (7) · Belgium (5) · Israel (5) · Switzerland (5)
Rui-hua Xu, MD, PhD (2) · Alan Tan, MD (1) · Ali Baghian, MD (1) · Amit Oza, M.D. (1) · Ana Oaknin, PhD (1) · Andres Poveda, MD (1) · Anish Thomas, MD (1) · Antonio Gonzalez, MD, PHD (1) · Ashish Sangal, MD (1)
PMID 36999619, PMID 19951879, PMID 23589315, PMID 23690414, PMID 24106841, PMID 26644411, PMID 26741729, PMID 26842696, PMID 27148765, PMID 27959684, PMID 28065465, PMID 29119276, PMID 30683863, PMID 30943124, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32379269, PMID 32792420, PMID 32918045, PMID 32919526, PMID 33109737, PMID 33148673, PMID 33152282, PMID 33277223, PMID 33329935, PMID 33477979, PMID 33836153, PMID 34161704, PMID 34592180, PMID 34615718, PMID 34990208, PMID 35114169, PMID 35167329, PMID 35275706, PMID 35361487, PMID 35404402, PMID 35444013, PMID 35588692, PMID 35658005, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36129471, PMID 36328377, PMID 36342102, PMID 36546659, PMID 36748723, PMID 36821617, PMID 36868252
2015 (5), 2018 (5), 2019 (3), 2017 (2), 2023 (2), 2014 (1), 2016 (1), R01NR010162 (1)